Osteocalcin modulates parathyroid cell function in human parathyroid tumors

Introduction The bone matrix protein osteocalcin (OC), secreted by osteoblasts, displays endocrine effects. We tested the hypothesis that OC modulates parathyroid tumor cell function. Methods Primary cell cultures derived from parathyroid adenomas (PAds) and HEK293 cells transiently transfected with the putative OC receptor GPRC6A or the calcium sensing receptor (CASR) were used as experimental models to investigate γ-carboxylated OC (GlaOC) or uncarboxylated OC (GluOC) modulation of intracellular signaling. Results In primary cell cultures derived from PAds, incubation with GlaOC or GluOC modulated intracellular signaling, inhibiting pERK/ERK and increasing active β-catenin levels. GlaOC increased the expression of PTH, CCND1 and CASR, and reduced CDKN1B/p27 and TP73. GluOC stimulated transcription of PTH, and inhibited MEN1 expression. Moreover, GlaOC and GluOC reduced staurosporin-induced caspase 3/7 activity. The putative OC receptor GPRC6A was detected in normal and tumor parathyroids at membrane or cytoplasmic level in cells scattered throughout the parenchyma. In PAds, the membrane expression levels of GPRC6A and its closest homolog CASR positively correlated; GPRC6A protein levels positively correlated with circulating ionized and total calcium, and PTH levels of the patients harboring the analyzed PAds. Using HEK293A transiently transfected with either GPRC6A or CASR, and PAds-derived cells silenced for CASR, we showed that GlaOC and GluOC modulated pERK/ERK and active β-catenin mainly through CASR activation. Conclusion Parathyroid gland emerges as a novel target of the bone secreted hormone osteocalcin, which may modulate tumor parathyroid CASR sensitivity and parathyroid cell apoptosis.

[1]  J. Vitale,et al.  Circulating Carboxylated Osteocalcin Correlates With Skeletal Muscle Mass and Risk of Fall in Postmenopausal Osteoporotic Women , 2021, Frontiers in Endocrinology.

[2]  Jeremy C. Smith,et al.  The carboxylation status of osteocalcin has important consequences for its structure and dynamics. , 2020, Biochimica et biophysica acta. General subjects.

[3]  T. Komori.  Functions of Osteocalcin in Bone, Pancreas, Testis, and Muscle , 2020, International journal of molecular sciences.

[4]  S. Corbetta,et al.  Intratumor heterogeneity in human parathyroid tumors. , 2020, Histology and histopathology.

[5]  R. Thakker,et al.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function , 2020, Pharmacological Reviews.

[6]  H. Bräuner‐Osborne,et al.  Pharmacology and physiological function of the orphan GPRC6A receptor. , 2020, Basic & clinical pharmacology & toxicology.

[7]  A. Arya,et al.  Dysregulated mitogen-activated protein kinase pathway mediated cell cycle disruption in sporadic parathyroid tumors , 2020, Journal of Endocrinological Investigation.

[8]  Yong Wang,et al.  Matrix Gla Protein Promotes the Bone Formation by Up-Regulating Wnt/β-Catenin Signaling Pathway , 2019, Front. Endocrinol..

[9]  S. Minisola,et al.  The Endocrine Function of Osteocalcin Regulated by Bone Resorption: A Lesson from Reduced and Increased Bone Mass Diseases , 2019, International journal of molecular sciences.

[10]  Yupei Zhao,et al.  Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas , 2018, International journal of cancer.

[11]  J. Villafan-Bernal,et al.  Osteocalcin-GPRC6A: An update of its clinical and biological multi-organic interactions , 2018, Molecular medicine reports.

[12]  Wenjun Wu,et al.  Effects of FGF‐23‐mediated ERK/MAPK signaling pathway on parathyroid hormone secretion of parathyroid cells in rats with secondary hyperparathyroidism , 2018, Journal of cellular physiology.

[13]  I. Z̆ofková.  Involvement of bone in systemic endocrine regulation. , 2018, Physiological research.

[14]  F. Cetani,et al.  The aberrantly expressed miR-372 partly impairs sensitivity to apoptosis in parathyroid tumor cells. , 2018, Endocrine-related cancer.

[15]  G. Karsenty,et al.  Osteocalcin in the brain: from embryonic development to age-related decline in cognition , 2018, Nature Reviews Endocrinology.

[16]  M. Lenhard,et al.  Effect of parathyroidectomy on osteopontin and undercarboxylated osteocalcin in patients with primary hyperparathyroidism , 2018, Endocrine research.

[17]  A. Bergenfelz,et al.  Predictors of multiglandular disease in primary hyperparathyroidism , 2018, Langenbeck's Archives of Surgery.

[18]  P. Makras,et al.  Bone disease in primary hyperparathyroidism. , 2017, Metabolism: clinical and experimental.

[19]  F. Gao,et al.  Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells , 2017, Cellular Physiology and Biochemistry.

[20]  F. Cetani,et al.  Expression, function, and regulation of the embryonic transcription factor TBX1 in parathyroid tumors. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[21]  E. Schadt,et al.  Genomic profiling reveals mutational landscape in parathyroid carcinomas. , 2017, JCI insight.

[22]  K. Gregory,et al.  Molecular insights into allosteric modulation of Class C G protein-coupled receptors. , 2017, Pharmacological research.

[23]  L. Quarles,et al.  GPRC6A: Jack of all metabolism (or master of none) , 2016, Molecular metabolism.

[24]  M. Nogueira-Barbosa,et al.  Primary Hyperparathyroidism: The Influence of Bone Marrow Adipose Tissue on Bone Loss and of Osteocalcin on Insulin Resistance , 2016, Clinics.

[25]  Jeremy C. Smith,et al.  Evidence for Osteocalcin Binding and Activation of GPRC6A in β-Cells. , 2016, Endocrinology.

[26]  J. Bilezikian,et al.  Primary Hyperparathyroidism , 2016, F1000Research.

[27]  G. Karsenty,et al.  GGCX and VKORC1 inhibit osteocalcin endocrine functions , 2015, The Journal of cell biology.

[28]  Takahito Otani,et al.  Signaling pathway for adiponectin expression in adipocytes by osteocalcin. , 2015, Cellular signalling.

[29]  A. Avogaro,et al.  Uncarboxylated osteocalcin stimulates 25-hydroxy vitamin D production in Leydig cell line through a GPRC6a-dependent pathway. , 2014, Endocrinology.

[30]  D. Guidolin,et al.  Carboxylation-dependent conformational changes of human osteocalcin. , 2014, Frontiers in bioscience.

[31]  M. Tohyama,et al.  L-Arginine Stimulates Fibroblast Proliferation through the GPRC6A-ERK1/2 and PI3K/Akt Pathway , 2014, PloS one.

[32]  P. Wellendorph,et al.  The GPCR, class C, group 6, subtype A (GPRC6A) receptor: from cloning to physiological function , 2014, British journal of pharmacology.

[33]  J. Park,et al.  The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway. , 2013, Metabolism: clinical and experimental.

[34]  L. Boise,et al.  Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis , 2013, BMC Cell Biology.

[35]  L. Quarles,et al.  GPRC6A regulates prostate cancer progression , 2012, The Prostate.

[36]  Yunpeng Wu,et al.  GPRC6A mediates responses to osteocalcin in β‐cells in vitro and pancreas in vivo , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  L. Gianotti,et al.  Interplay Between Serum Osteocalcin and Insulin Sensitivity in Primary Hyperparathyroidism , 2011, Calcified Tissue International.

[38]  D. Cusi,et al.  Calcimimetic R-568 effects on activity of R990G polymorphism of calcium-sensing receptor. , 2010, Journal of molecular endocrinology.

[39]  A. Conigrave,et al.  Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development. , 2010, Pharmacology & therapeutics.

[40]  P. Beck‐Peccoz,et al.  Modulation of cyclin D1 expression in human tumoral parathyroid cells: effects of growth factors and calcium sensing receptor activation. , 2007, Cancer letters.

[41]  G. Blandino,et al.  p73-induced apoptosis: a question of compartments and cooperation. , 2005, Biochemical and biophysical research communications.

[42]  J. Silver,et al.  Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. , 2005, Kidney international. Supplement.

[43]  E. Brown,et al.  Decreased expression of caveolin-1 and altered regulation of mitogen-activated protein kinase in cultured bovine parathyroid cells and human parathyroid adenomas. , 2003, The Journal of clinical endocrinology and metabolism.

[44]  M. Bouxsein,et al.  Osteoblast-specific Knockout of the Insulin-like Growth Factor (IGF) Receptor Gene Reveals an Essential Role of IGF Signaling in Bone Matrix Mineralization* , 2002, The Journal of Biological Chemistry.

[45]  A. Lania,et al.  Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells. , 2002, The Journal of clinical endocrinology and metabolism.

[46]  Beretta,et al.  Calcium‐sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia , 2000, Clinical endocrinology.

[47]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[48]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[49]  J B Lian,et al.  Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. , 1989, Physiological reviews.

[50]  T. Clemens,et al.  New insights into the biology of osteocalcin. , 2016, Bone.